Physician profile
Suneel Kumar
NPI 1811934839
$5,108.99
in general payments reported to CMS, 2019-2025
44 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $520 · 2021: $608 · 2022: $813 · 2023: $1,214 · 2024: $1,139 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,886 · Education: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,886.35 |
| Education | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,388.37 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $562.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Grifols USA, LLC | $409.30 | 2019-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $290.14 | 2020-2024 | Wakix |
| United Therapeutics Corporation | $276.57 | 2019-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $149.18 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.56 | 2020-2023 | Spiriva Respimat, Stiolto Respimat |
| Philips North America LLC | $135.85 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Jazz Pharmaceuticals INC. | $127.02 | 2021-2023 | Xywav |
| Pulmonx Corporation | $112.92 | 2021-2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Heartflow, INC. | $109.07 | 2024 | |
| Electromed, INC. | $105.56 | 2021-2024 | Smartvest |
| Novartis Pharmaceuticals Corporation | $94.05 | 2019-2023 | |
| Gilead Sciences, INC. | $93.07 | 2021-2023 | Veklury |
| Mylan Specialty L.P. | $83.05 | 2019-2024 | Yupelri |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $82.98 | 2021-2025 | Dupixent |
| Amgen INC. | $66.18 | 2022-2024 | Tezspire |
| Axsome Therapeutics, INC. | $66.16 | 2023-2025 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $61.33 | 2020-2024 | Glassia |
| Alexion Pharmaceuticals, INC. | $59.81 | 2021-2022 | |
| Baxter Healthcare | $58.25 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Ani Pharmaceuticals, INC. | $54.14 | 2022 | |
| Inogen, INC. | $49.72 | 2022-2025 | |
| Insmed, INC. | $46.29 | 2023-2025 | Arikayce |
| Sunovion Pharmaceuticals INC. | $44.88 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.23 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $38.28 | 2023-2024 | Acthar |
| Pharming Healthcare, INC. | $28.94 | 2023 | Ruconest |
| Viatris Specialty LLC | $27.16 | 2025 | Yupelri |
| Abbvie INC. | $25.42 | 2021 | |
| Boston Scientific Corporation | $23.86 | 2022 | |
| Recor Medical INC | $23.61 | 2025 | Paradise Ultrasound Renal Denervation System |
| Actelion Pharmaceuticals US, INC. | $21.80 | 2021 | |
| Genentech USA, INC. | $20.82 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.79 | 2022 | |
| Ethicon INC. | $20.56 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.45 | 2024 | Nuzyra |
| Tactile Systems Technology INC | $20.36 | 2025 | Nimbl, Flexitouch Plus |
| Verona Pharma, INC. | $20.15 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $19.68 | 2024 | Zerbaxa, Recarbrio |
| Amarin Pharma, INC. | $18.39 | 2020 | |
| Veran Medical Technologies, INC. | $17.76 | 2019 | |
| Shire North American Group INC | $14.31 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.18 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suneel Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.